October 18 2025 – Pfizer Inc. reported strong global engagement ahead of IDWeek 2025 in Atlanta, where the company presented findings from 46 clinical and real-world vaccine studies covering COVID-19, RSV, pneumococcal (Prevnar 20), Lyme, and meningococcal platforms. Pfizer highlighted its leadership in respiratory disease prevention and ongoing innovation across its infectious disease portfolio. The company’s senior vaccine executives emphasized cooperation with the WHO and CDC on next-generation immunization priorities. October 13 2025 – GSK plc unveiled new phase 3 clinical results during the World Vaccine Congress Europe 2025 (Amsterdam), demonstrating the safety and efficacy of its next-generation RSV vaccine (2026 formulation) and a bivalent meningococcal program for adolescents and young adults. GSK executives presented data supporting broader combination use across Northern Hemisphere seasonal deployments. The update reinforces the company’s strategy to dominate respiratory and meningococcal markets through innovation. October 10 2025 – Moderna Inc. shared its plan to release ten new...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
